PepGen to Advance PGN-EDODM1 Into Highest Dose Cohort in Phase 2 FREEDOM2-DM1 Study Following DSMB Review
Business Wire•06/08/2026•07:30 ET
0
Whiz Insights
Get started
Create a free account to read the full story.
Create a free account to read the full story.